Description

Arix Bioscience plc operates as a venture capital firm, focusing its investments across the entire lifecycle of companies, from nascent seed-stage ventures and preclinical or clinical asset development to early, mid, and late-stage growth capital rounds, encompassing both private and public equity. The firm's investment mandate is global, targeting the biotechnology sector and seeking out entities involved in groundbreaking therapeutics, cutting-edge technologies, and broader medical innovations spanning healthcare and life sciences. Employing an evergreen funding model, Arix Bioscience predominantly deploys capital directly from its own balance sheet. It generally prefers to secure a board position within its portfolio companies and strategically exits investments once the peak value has been realized. Established in 2015 and headquartered in London, United Kingdom, the company was previously known as Perceptive Bioscience Investments Limited.